South Korea
· Delayed Price · Currency is KRW Curocell Statistics
Total Valuation
Curocell has a market cap or net worth of KRW 379.83 billion. The enterprise value is 405.35 billion.
| Market Cap | 379.83B |
| Enterprise Value | 405.35B |
Important Dates
The next estimated earnings date is Thursday, April 3, 2025.
| Earnings Date | Apr 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Curocell has 14.20 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 14.20M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 33.93% |
| Owned by Institutions (%) | 10.64% |
| Float | 9.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 12.90 |
| P/TBV Ratio | 13.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.60 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.04 |
Financial Position
The company has a current ratio of 0.34, with a Debt / Equity ratio of 1.27.
| Current Ratio | 0.34 |
| Quick Ratio | 0.30 |
| Debt / Equity | 1.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.29 |
| Interest Coverage | -14.07 |
Financial Efficiency
Return on equity (ROE) is -86.36% and return on invested capital (ROIC) is -27.13%.
| Return on Equity (ROE) | -86.36% |
| Return on Assets (ROA) | -25.87% |
| Return on Invested Capital (ROIC) | -27.13% |
| Return on Capital Employed (ROCE) | -110.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.35% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -15.35% |
| 50-Day Moving Average | 29,367.00 |
| 200-Day Moving Average | 29,281.90 |
| Relative Strength Index (RSI) | 39.64 |
| Average Volume (20 Days) | 58,062 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -10.49M |
| Operating Income | -36.62B |
| Pretax Income | -38.24B |
| Net Income | -38.24B |
| EBITDA | -30.29B |
| EBIT | -36.62B |
| Earnings Per Share (EPS) | -2,736.20 |
Balance Sheet
The company has 11.78 billion in cash and 37.30 billion in debt, giving a net cash position of -25.52 billion or -1,797.23 per share.
| Cash & Cash Equivalents | 11.78B |
| Total Debt | 37.30B |
| Net Cash | -25.52B |
| Net Cash Per Share | -1,797.23 |
| Equity (Book Value) | 29.45B |
| Book Value Per Share | 2,074.34 |
| Working Capital | -25.70B |
Cash Flow
In the last 12 months, operating cash flow was -28.42 billion and capital expenditures -441.02 million, giving a free cash flow of -28.86 billion.
| Operating Cash Flow | -28.42B |
| Capital Expenditures | -441.02M |
| Free Cash Flow | -28.86B |
| FCF Per Share | -2,032.70 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Curocell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -10.07% |
| FCF Yield | -7.60% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |